Medical Developments International

4 February 2015

ASX ANNOUNCEMENT

CEO Roadshow Presentation Slides

Medical Developments International Limited (ASX: MVP) will hold a CEO Roadshow in Melbourne and Sydney on the 4th and 5th February 2015 talking to the attached presentation to interested Fund Managers.

Enquiries:

David Williams
Chairman
Medical Developments International Ltd
0414 383 593

John Sharman
Chief Executive Officer
Medical Developments International Ltd
03 9547 1888

About Penthrox

Penthrox is a fast onset, non-opioid analgesic indicated for pain relief by self-administration in patients with trauma and those requiring analgesia for surgical procedures. Penthrox has been used safely and effectively for more than 30 years in Australia with excess of 5.0 million units sold. There is growing interest in Penthrox being used in patients undergoing investigatory procedures, as well as operational procedures such as colonoscopy.

About Medical Developments International Ltd

MVP is an Australian company delivering emergency medical solutions dedicated to improving patient outcomes. MVP is a leader in emergency pain relief and respiratory products. The Company manufactures Penthrox®, a fast acting minor trauma & emergency pain relief product. It is used in Australian Hospitals including Emergency Departments, Australian Ambulance Services, the Australian Defence Forces, Sports Medicine and for analgesia during short surgical procedures such as Dental and Cosmetic surgery as well as in other medical applications. MVP is expanding internationally and manufactures a range of world-leading Asthma respiratory devices.

Medical Developments International Limited ABN 14 106 340 667
7/56 Smith Road Springvale Victoria 3171 Australia **Postal Address** PO Box 21 Sandown Village Victoria 3171 Australia
Telephone +61 3 9547 1888 **Fax** +61 3 9547 0262 **Web** www.medicaldev.com

Medical Developments International

Medical
Developments
International

Vision

Medical Developments International (MDI) is a leading Emergency Medicine Company.

Our aim is to

1. Dominate the analgesic trauma and minor surgical procedures market domestically and internationally
2. Dominate the Respiratory Medical Devices market domestically and internationally
3. Provide unique and innovative products to assist our customers in the management of acute and procedural pain, delivery of respiratory medications, resuscitation and oxygen therapies for human and veterinary patients.

Medical Developments International

Vision

MDI is working on and delivering two significant business opportunities.

Both opportunities are “company making”.

The risk profile of these opportunities is relatively low and well understood.

- Penthrox: Our regulatory initiatives if successful will transform the company. Penthrox has the potential to be the market leader in emergency analgesic markets in Europe and elsewhere
- Our Respiratory medical devices should generate significant growth

Medical Developments International

Two world class opportunities

Penthrox

- Significant competitive advantages to other analgesics.
- Fast, safe, rapid on-set, effective, cost-competitive, self administered.
- No needles, non-opiate, easy to store & transport.
- Building world class regulatory dossier to enable sales of Penthrox in other countries around the world.
- Completed successful phase lll trials in Europe.
- Completed other successful clinical trials.
- Positive feedback from European Regulatory Authorities and working towards approval during FY15.
- Working on reducing the cost to compete with other analgesics.

Medical Developments International

Two world class opportunities

Respiratory medical devices

- Leading patented asthma & COPD medicine delivery devices.
- Low resistance, more efficient medicine dosage delivery.
- Won international tenders and major contracts in NZ, Canada, Germany & Australia to supply “Space Chambers”.
- Lodged US FDA application.
- Independent testing prove “best delivery of medicine”.
- Significant growth in Asthma device sales since 2011.
- Increasing customer base – recently established European head office & distributors – recently established North American head office.

Medical Developments International

MDI Corporate Overview

Three business divisions

- Pharmaceutical.
- Medical devices.
- Veterinary.

We have a widely recognised portfolio of brands such as

- Penthrox;
- Space Chamber;
- Space Chamber Plus;
- OXI-Port;
- OXI-Sok;
- KAB Absorber; and
- OXI-Life.

Medical Developments International

MDI Corporate Overview

MDI is recognised as a leader in pain relief, emergency medical devices; oxygen therapies and respiratory products. Our products are the first choice of professionals in the hospital, pre-hospital, first aid environments, universities and veterinary institutions.

Medical Developments International (MDI) commenced operations in 1972 and listed as a public company in December 2003.

MDI design, manufacture and distribute innovative healthcare products within Australia and Internationally and is located in Melbourne, Australia.

Our products are used in 11 countries with the list of new country registrations increasing.

Our manufacturing facilities are ISO 13485, GMP compliant.

Medical Developments International

MDI Pharmaceutical

Penthrox®

- Inhalational analgesic
- Demonstrated safety and efficacy profile
- Only manufacturer in the world
- Sold in Australia, N.Z, GCC
  South America, Eastern Europe & others
- Manufactured in GMP compliant plant

Medical
Developments
International

Penthrox
Clinical application

- Burn injuries
- Breaks, fractures and dislocations
- Abdomen pain
- Chest pain
- Other acute pain



Painful procedures

- Cutaneous excisions
- Liquid nitrogen removals of skin-cancers, warts, etc
- Invasive angiographies
- Dental procedures
- Colonoscopy
- Imaging
- Other non-general anaesthetic painful procedures

Either as an adjunct to or replacement of current forms of pain relief.

Medical Developments International

Penthrox
Benefits to medical professionals

Rapid onset of action	Minimal waiting time before a painful procedure can be performed (3 minutes) and rapid pain relief when a patient is treated for burns, trauma, etc.
Inhaled self-administration	Medical professionals can perform a procedure/attend to an injury whilst the patient is self-administering with minimal supervision needed.
Improve patient compliance	Effective at calming patients before procedures; makes patients more compliant and cooperative during treatments/procedures.
Portable, easy to use	Easy to store in a range of clinical settings (doctor's bag, ambulance, GP/specialist consulting rooms, hospital departments, military unit, etc.)

Medical Developments International

Penthrox
Benefits over Nitrous Oxide

Penthrox® does not effect vital signs; no clinical depression of respiration or circulation at low analgesic dosing.

Self-administration, easy to use and administer.

Compact and can be used in any location or situation.

No risk of overdose.

Single use device ensures no cleaning or cross contamination.

Medical professionals can perform a procedure / attend to an injury almost immediately whilst the patient is self-administering with minimal supervision.

Offset ranges from 3-5 minutes up to 20 minutes.

Easy and stable to store.

Patients can drive themselves home.

Medical Developments International

Penthrox
Benefits over Morphine

The benefits of using Penthrox® over Morphine are the same as detailed for Nitrous. In addition there are a number of specific benefits Penthrox has over Morphine which include:

Penthrox can be used on children, Morphine often cannot

Penthrox is not a narcotic; opioid or drug of addiction

Penthrox has less severe side effects

Penthrox is non invasive – no needles

Penthrox has a quicker onset to pain relief

Penthrox can be used by a wider community of health professionals including first aiders and volunteers

Morphine has considerable and complex administration and monitoring protocols during its use and for a significant time during recovery.

Penthrox does not require specific storage and use protocols

Medical Developments International

Penthrox
Future

MDI has signed a deal with CSIRO to develop a new manufacturing technique for Penthrox

If successful this will provide MDI with:

1. World leading intellectual property
2. Very significant increased production capacity
3. Very significant reduction in cost to manufacture
4. Very significant competitive advantage

Medical Developments International

Penthrox
Future

Our aim is to create a world class regulatory dossier capable of gaining approval to sell Penthrox anywhere in the world.

MDI has spent more than $7 million on developing a regulatory dossier capable of getting Penthrox approved for sale in other countries.

Our Marketing Application was submitted to European authorities during 2013. We have received positive feedback from the authorities indicating that Penthrox is “approvable” subject to completing a number of tasks.

We are working towards achieving formal approval in the coming months.

Medical Developments International

Penthrox
Future

MDI is working on regulatory approvals to expand into new countries in Europe, Central America, Canada, Asia, Africa, Russia, Israel, Saudi Arabia. The following numbers are MDI estimates of the market potential for Penthrox in Europe:

		AUD million
EUROPE	Penthrox potential sales	$422

		AUD million
UK	Penthrox potential sales	$40
France	Penthrox potential sales	$37
Germany	Penthrox potential sales	$38
Italy	Penthrox potential sales	$36
Spain	Penthrox potential sales	$28
Rest of Europe	Penthrox potential sales	$243

Medical Developments International

Penthrox
Future

Our plan is to use the Regulatory dossier to improve the positioning and obtain approvals to sell Penthrox around the world.

We are developing new Penthrox products which could deliver IP protection.

We are developing a new manufacturing methodology to make Penthrox.

If successful it may be possible to sell millions of units of Penthrox per year.

Medical Developments International

MDI Medical
Respiratory division

Since 1985 Medical Developments International has invested significant R&D resources to improving the delivery of Asthma and COPD medication.

In 2011 MDI launched the Space Chamber Plus® and the Compact Space Chamber Plus® in the Australian and International markets.

Both these spacers include MDI's Cross Valve Technology ™, a patented system of drug delivery which ensures very low resistance during inhalation and exhalation, while maximizing the dose of medication available.

MDI products are world leaders in their field.

Medical Developments International

MDI Medical
Respiratory division

MDI offers a range of innovative world leading devices that can be used to help patients manage and take control of their asthma and COPD.

- Space Chamber Plus® aerosol spacer
- Space Chamber® re-usable
- Compact Spacer Chamber Plus®
- Breath-Alert® peak flow meter
- EZ-fit face masks
- KDK oxygen regulators

Medical Developments International

MDI Medical
Respiratory division

MDI Space Chamber Plus ®

- Recently approved by the FDA for sale in the USA.
- Recently registered by MHRA for full reimbursement.
- Won an international tender in New Zealand to supply MDI's range of asthma products exclusively for three years.
  - ✓ Defeated more than 10 international bidders.
- German distributor replaced its entire range of competitors products with MDI's Space Chambers.
- Won a tender to supply Canadian Hospitals with MDI's Space Chamber for 5 years.

Medical Developments International

MDI Medical
Respiratory division

MDI Space Chamber Plus ®

- New patent cross valve technology
- Universal end suitable for all Metered Dose Inhalers
- Compact design
- Provides very low resistance for both inhalation and exhalation
- Enables unrestricted and continuous breathing
- Performance equivalent to worlds best practice for inhalers
- Transparent design to allow you to see medication delivery
- Superior looks
- Can be used with any international standard facemask
- Best value

Medical Developments International

MDI Medical
Respiratory division

The MDI Space Chamber Plus®is worlds best practice for delivering Asthma medications

Flixotide, 125 µg/actuation; Canister Batch numbers: AN9158 (Exp APR/13)

Device		Weight of drug per actuation (µg)		% drug per actuation	
		Exiting Spacer	Particles < 3.99 µm	Exiting Spacer	Particles < 3.99 µm
SpaceChamber *plus* (n=6)	Mean	58.7	47.6	52.6	42.7
	SD	4.9	4.5	3.0	3.1
	CV	8.3	9.6	5.7	7.4
AeroChamber *plus* (n=6)	Mean	46.6	39.5	41.3	35.0
	SD	6.4	4.7	4.9	3.9
	CV	13.7	12.0	11.9	11.0
Breath-A-Tec (n=6)	Mean	43.3	37.7	38.3	33.4
	SD	7.5	6.6	6.7	6.1
	CV	17.2	17.4	17.5	18.4

Medical Developments International

References

1. Laboratory Usage of respiratory spacers and the delivered Fluticasone (Flixotide) dose of commonly used spacers available in Australia and New Zealand.

2.Output of Fluticasone (Flixotide) pressurized metered dose inhaler (pMDI) delivered via Space Chamber Plus, the Aerochamber and the Breath a Tech Spacer device. Data on file at MDI

Respiratory division
Future

Since 2012 we have obtained approval and signed distribution deals to sell our Space Chamber Plus' and other medical devices including

- USA
- UK
- UAE
- Denmark
- Netherlands
- Austria
- Singapore
- Switzerland
- Germany
- Canada
- Italy
- Greece
- Finland
- Hong Kong
- Malaysia

Medical Developments International

Respiratory division
Future

We now have business and are making sales in

Australia
Hong Kong
Belgium
Asia
Spain
New Zealand
Switzerland
UK
Canada
Germany
Greece
USA
UAE
Singapore
Malaysia
Netherlands
Italy
Denmark
Austria

Medical Developments International

Respiratory division
Future

MDI is investing heavily in developing new and innovative products

- Anti static spacers
- Anti static mask – (1st of its kind)
- Electronic peak flow
- Smart phone asthma & COPD applications

Medical Developments International

MDI Medical
Rescue and resuscitation

Our emergency medical equipment business has grown significantly since FY2011.

MDI is the preferred supplier in a number of markets including –



Ambulance, Non-emergency transport and Emergency First Aid

Various public and private health sectors (GP clinics, hospitals, aged care facilities) via wholesale and distribution channels

Medical Developments International

MDI Medical

Design, assemble and test a wide range of medical devices

ISO 13485 & GMP compliant assembly facilities

Over 30 devices in product portfolio

Focus on respiratory system and oxygen delivery

- Asthma management
- Oxygen delivery and equipment
- CO_2 absorbers
- Ventilators

Medical Developments International

MDI Veterinary

Design, assemble and test a wide range of veterinary devices

Focus on anaesthesia and surgical consumables

Anaesthesia

- Anaesthetic machines (closed circuit system)
- Breathing circuits
- Vaporisers



Medical Developments International

MDI
Global Strategy

New and revised materials and process
(lowest cost producer and significant IP)

Medical Developments International

MDI
Global Strategy

New and revised materials and process
(lowest cost producer and significant IP)

Product innovation
(worlds best delivery devices and significant IP)

Medical Developments International

MDI
Global Strategy

New and revised materials and process
(lowest cost producer and significant IP)

Product innovation
(worlds best delivery devices and significant IP)

Regulatory Approval and new markets

Medical Developments International

MDI
Global Strategy

New and revised materials and process
(lowest cost producer and significant IP)



Product innovation
(worlds best delivery devices and significant IP)

Clinical trials
(Commercial clinical studies to support marketing and product development)

Regulatory Approval and new markets

Medical Developments International

MDI
Global Strategy

New and revised materials and process
(lowest cost producer and significant IP)



New Business Partners

Product innovation
(worlds best delivery devices and significant IP)

Clinical trials
(Commercial clinical studies to support marketing and product development)

Regulatory Approval and new markets

Medical Developments International

Contact details

HEAD OFFICE

Factory 6 / 56 Smith Road PO Box 21
Springvale, VIC. 3171
Sandown Village, VIC. Australia

Tel: +61 3 9547 1888
Fax: +61 3 9547 0262
Web: www.medicaldev.com

Medical Developments International

Forward looking statements

This document contains certain forward looking statements relating to Medical Development International's business, which can be identified by the use of forward looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated"," targeting", "aiming", "set to", "potential"," seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track" or similar expressions or by express or implied discussion regarding potential filings or marketing approvals, or potential future sales of product. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy any health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Medical Development International Limited is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

Medical Developments International